BAM
VRPX

Belpointe Asset Management’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Belpointe Asset Management’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-76
Closed -$14.9K – 3606
2023
Q1 		$14.9K Hold
76
– – ﹤0.01% 2475
2022
Q4 		$11.9K Buy
+76
New +$17.3K ﹤0.01% 2528

Other funds holding VRPX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Belpointe Asset Management's VRPX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q2 2023, closing a stake of 76 shares — an estimated $14.9K sold.

Belpointe Asset Management first reported a position in VRPX in Q4 2022 and held it in 2 quarters. The position peaked at $14.9K in Q1 2023. 12 funds tracked by Wall St. Rank hold VRPX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 76 Virpax Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $14.9K.
  • Belpointe Asset Management first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $14.9K in Q1 2023.
  • 12 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.